Feb. 13 at 10:39 PM
$CDXS So this is what Im thinking is happening behind the scenes right now, Codexis is working with Nitto Avecia and Axolabs to quickly scale production of inclisiran (Leqvio) using the EcoSynthesis Platform, which they have both referred to as an 'evaluation'. This makes complete sense since Bachem has no production facilities here in the US and after reading the CEO of Novartis said three weeks ago they would get around tariffs by shifting production for US customers to manufacturing sites in the US in 2026. Their manufacturing hub they are breaking ground on in the US isn't anticipating to begin production until 2027 or 2028. Right now (2026) the US has around 1.6M that are eligible for Leqvio with another +20M potential additional patients currently on statins. An annual dosage per patient is approximately 900mg over three doses at around
$3300/dose. This would be VERY lucrative for Codexis to lead the charge on and hence all the secrecy!
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-expects-eliminate-us-tariff-exposure-by-mid2026-ceo-tells-cnbc-2026-01-20/
